Ian CPA - TNF Pharmaceuticals, Interim Officer
| TNFA Stock | 1.29 0.07 5.15% |
Executive
Ian CPA is Interim Officer of TNF Pharmaceuticals,
| Age | 51 |
| Address | 855 N. Wolfe Street, Baltimore, MD, United States, 21205 |
| Phone | 856 848 8698 |
| Web | https://tnfpharma.com |
TNF Pharmaceuticals, Management Efficiency
The company has return on total asset (ROA) of (0.3243) % which means that it has lost $0.3243 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9763) %, meaning that it created substantial loss on money invested by shareholders. TNF Pharmaceuticals,'s management efficiency ratios could be used to measure how well TNF Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. As of December 23, 2024, Return On Tangible Assets is expected to decline to -0.57. The current year's Return On Capital Employed is expected to grow to -1.26. At present, TNF Pharmaceuticals,'s Total Assets are projected to decrease significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to 1.21, whereas Non Current Assets Total are forecasted to decline to about 10.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Erica Osbourne | ESSA Pharma | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| Sebastien Maloveste | NextCure | N/A | |
| Robert Shoemaker | Erasca Inc | 43 | |
| Bonne MBA | Inhibrx | 47 | |
| Chandra MS | Erasca Inc | 53 | |
| Erin Rudsinski | ESSA Pharma | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Josep Garcia | Inhibrx | N/A | |
| Charbel PharmD | Inhibrx | N/A | |
| Elizabeth Gordon | Design Therapeutics | N/A | |
| MS MBA | Sensei Biotherapeutics | 46 | |
| MS CPA | Erasca Inc | 57 | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Kevin Shaw | NextCure | 49 | |
| Michael Varney | Erasca Inc | 66 | |
| Loleta Harris | ESSA Pharma | N/A | |
| Udayan MD | NextCure | N/A | |
| Richard MD | Lyra Therapeutics | 61 | |
| Neil Thapar | ESSA Pharma | N/A | |
| Carlos Bais | Inhibrx | N/A | |
Management Performance
| Return On Equity | -2.98 | ||||
| Return On Asset | -0.32 |
TNF Pharmaceuticals, Leadership Team
Elected by the shareholders, the TNF Pharmaceuticals,'s board of directors comprises two types of representatives: TNF Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TNF. The board's role is to monitor TNF Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. TNF Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TNF Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ian CPA, Interim Officer | ||
| Robert Schatz, Investor Officer | ||
| Mitchell MD, Chief President |
TNF Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is TNF Pharmaceuticals, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.98 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | (9.48 M) | ||||
| Shares Outstanding | 2.37 M | ||||
| Shares Owned By Insiders | 6.44 % | ||||
| Shares Owned By Institutions | 39.87 % | ||||
| Number Of Shares Shorted | 279.28 K | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (4 M) | ||||
| Net Income | (4 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether TNF Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of TNF Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tnf Pharmaceuticals, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tnf Pharmaceuticals, Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TNF Pharmaceuticals,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. For information on how to trade TNF Stock refer to our How to Trade TNF Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TNF Pharmaceuticals,. If investors know TNF will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TNF Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.48) | Return On Assets (0.32) | Return On Equity (2.98) |
The market value of TNF Pharmaceuticals, is measured differently than its book value, which is the value of TNF that is recorded on the company's balance sheet. Investors also form their own opinion of TNF Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is TNF Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TNF Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect TNF Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TNF Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if TNF Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TNF Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.